STOCK TITAN

[Form 4] Guardant Health, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4

Helmy Eltoukhy, Co-CEO and director of Guardant Health (GH), filed a Form 4 reporting open-market sales of the company’s common stock on 09/09/2025. The filing shows two sale transactions: 294,723 shares sold at a weighted average price of $59.4447 and 5,277 shares sold at a weighted average price of $59.9346. After these sales the reported beneficial ownership was 2,128,776 shares and 2,123,499 shares, respectively. Footnotes state the larger block sold at prices ranging from $58.79 to $59.78 and the smaller block from $59.79 to $60.25, with a weighted average reported for each block.

The Form 4 is signed by an attorney-in-fact on behalf of Mr. Eltoukhy and contains no additional commentary, option transactions, or other derivative activity.

Helmy Eltoukhy, Co-CEO e direttore di Guardant Health (GH), ha presentato un Form 4 segnalando vendite nel mercato aperto delle azioni ordinarie dell’azienda in data 09/09/2025. La comunicazione mostra due transazioni di vendita: 294.723 azioni vendute a un prezzo medio ponderato di 59,4447 dollari e 5.277 azioni vendute a un prezzo medio ponderato di 59,9346 dollari. Dopo queste vendite la proprietà beneficiaria reportata era rispettivamente 2.128.776 azioni e 2.123.499 azioni. Le note a piè pagina indicano che il blocco più grande è stato venduto a prezzi che vanno da 58,79 a 59,78 dollari e il blocco minore da 59,79 a 60,25 dollari, con un prezzo medio ponderato riportato per ciascun blocco.

Il Form 4 è firmato da un procuratore ad acta per conto del signor Eltoukhy e non contiene ulteriori commenti, operazioni su opzioni o altre attività derivanti.

Helmy Eltoukhy, co-CEO y director de Guardant Health (GH), presentó un Formulario 4 informando ventas en el mercado abierto de las acciones comunes de la compañía el 09/09/2025. La presentación muestra dos transacciones de venta: 294.723 acciones vendidas a un precio medio ponderado de 59,4447 dólares y 5.277 acciones vendidas a un precio medio ponderado de 59,9346 dólares. Después de estas ventas, la titularidad beneficiosa reportada fue 2.128.776 acciones y 2.123.499 acciones, respectivamente. Las notas al pie señalan que el bloque más grande se vendió a precios entre 58,79 y 59,78 dólares y el bloque más pequeño entre 59,79 y 60,25 dólares, con un precio medio ponderado informado para cada bloque. El Formulario 4 está firmado por un apoderado en nombre del señor Eltoukhy y no contiene comentarios adicionales, transacciones de opciones u otra actividad derivada.

헬미 엘투키(Helmy Eltoukhy), Guardant Health(GH)의 공동 최고경영자(CEO) 겸 이사, 2025년 9월 9일 공시된 Form 4를 통해 회사의 보통주를 공개시장에서 매도했다는 정보를 제출했습니다. 공시에는 두 건의 매도 거래가 표시됩니다: 29만 4723주가 가중평균가 59.4447달러로 매도5,277주가 가중평균가 59.9346달러로 매도. 이 매도 후 보고된 수혜 소유권은 각각 2,128,776주2,123,499주로 기재됩니다. 각 블록에 대해 가중평균가가 보고되었으며, 주석에 따르면 대형 블록은 58.79~59.78달러 구간에서, 소형 블록은 59.79~60.25달러 구간에서 매도된 것으로 기재되어 있습니다.

Form 4는 엘투키 씨를 대신하여 대리인이 서명했고, 추가 코멘트나 옵션 거래, 또는 기타 파생상품 활동은 포함되어 있지 않습니다.

Helmy Eltoukhy, co-PDG et administrateur de Guardant Health (GH), a déposé un Formulaire 4 déclarant des ventes sur le marché libre d’actions ordinaires de la société le 09/09/2025. Le dépôt montre deux transactions de vente : telles que 294 723 actions vendues à un prix moyen pondéré de 59,4447 $ et 5 277 actions vendues à un prix moyen pondéré de 59,9346 $. Après ces ventes, la propriété bénéficiaire déclarée était respectivement 2 128 776 actions et 2 123 499 actions. Les notes de bas de page indiquent que le bloc le plus important a été vendu à des prix allant de 58,79 $ à 59,78 $ et le bloc le plus petit de 59,79 $ à 60,25 $, avec un prix moyen pondéré affiché pour chaque bloc. Le Formulaire 4 est signé par un mandataire agissant au nom de M. Eltoukhy et ne contient aucun commentaire supplémentaire, ni transactions d’options ou autres activités dérivées.

Helmy Eltoukhy, Co-CEO und Direktor von Guardant Health (GH), hat ein Form 4 eingereicht, das Offenmarktverkäufe von Stammaktien des Unternehmens am 09.09.2025 meldet. Die Einreichung zeigt zwei Verkaufstransaktionen: 294.723 Aktien zu einem gewichteten Durchschnittspreis von 59,4447 USD und 5.277 Aktien zu einem gewichteten Durchschnittspreis von 59,9346 USD. Nach diesen Verkäufen betrug die gemeldete wirtschaftliche Eigentümerschaft jeweils 2.128.776 Aktien bzw. 2.123.499 Aktien. Fußnoten geben an, dass der größere Block zu Preisen zwischen 58,79 USD und 59,78 USD verkauft wurde und der kleinere Block zwischen 59,79 USD und 60,25 USD, mit einem gewichteten Durchschnittspreis für jeden Block. Das Form 4 ist von einem Bevollmächtigten im Namen von Herrn Eltoukhy unterzeichnet und enthält keine weiteren Kommentare, Optionsgeschäfte oder andere Derivateaktivitäten.

هيلمي التوخي، الرئيس التنفيذي المشارك ومدير في Guardant Health (GH)، قدم نموذج 4 للإبلاغ عن مبيعات في السوق المفتوحة للأسهم العادية للشركة في 09/09/2025. يظهر التسجيل صفقتين للبيع: بيع 294,723 سهمًا بسعر متوسط موزون قدره 59.4447 دولارًا وبيع 5,277 سهمًا بسعر متوسط موزون قدره 59.9346 دولارًا. بعد هذه المبيعات، كانت الملكية المستفيدة المبلغ عنها على التوالي 2,128,776 سهمًا و2,123,499 سهمًا. تشير الهوامش إلى أن الكتلة الأكبر بيعت بأسعار تتراوح من 58.79 إلى 59.78 دولارًا، والكتلة الأصغر من 59.79 إلى 60.25 دولارًا، مع سعر متوسط موزون مُعلن لكل كتلة. Form 4 موقّع من وكيل قضائي نيابة عن السيد Eltoukhy ولا يحتوي على تعليقات إضافية أو صفقات خيارات أو أنشطة مشتقة أخرى.

Helmy Eltoukhy,Guardant Health(GH)的联合首席执行官兼董事,已提交 Form 4,就公司普通股在公开市场的交易于 2025-09-09 报告了出售情况。 该备案显示两笔出售交易:出售 294,723 股,加权平均价格为 59.4447 美元出售 5,277 股,加权平均价格为 59.9346 美元。在这两笔交易之后,申报的受益所有权分别为 2,128,776 股2,123,499 股。脚注指示,大宗交易的价格区间在 58.79 至 59.78 美元,小宗交易在 59.79 至 60.25 美元,均给出各自的加权平均价。表格 Form 4 由代表 Eltoukhy 先生的代理律师签署,未包含额外评论、期权交易或其他衍生品活动。

Positive
  • Insider retains a substantial holding with reported beneficial ownership of 2,128,776 and 2,123,499 shares after the reported sales
  • Filing provides weighted-average prices and explicit price ranges, enhancing transparency about the transactions
Negative
  • Material open-market sales reported: 294,723 shares at a weighted average of $59.4447 and 5,277 shares at a weighted average of $59.9346
  • Form does not indicate a 10b5-1 plan (the plan checkbox is not checked), so the filing gives no automated-plan context for the timing of the sales

Insights

TL;DR: A senior insider sold a material block of shares but retains a multi-million share holding; disclosure is clear and routine.

The reported open-market sales on a single date by the Co-CEO and director are material in the sense of being non-trivial share disposals disclosed under Section 16. The filing provides weighted-average prices and explanatory ranges, satisfying standard disclosure norms. Retention of over 2.1 million shares after the transactions indicates the insider remains a significant shareholder. The filing lacks any indication that sales were pursuant to a Rule 10b5-1 plan; the form does not check the plan box.

TL;DR: Two reported sales totaling 299,...shares at roughly $59.45–$59.93; transaction details are precise but convey no operational signal.

The Form 4 quantifies the exact share amounts and weighted-average prices and includes footnotes with price ranges for multiple trades. There are no derivative transactions or amendments disclosed. From a market-impact perspective, the disclosure is actionable for transparency but does not include context such as purpose of sale. The clear numeric detail supports accurate modeling of insider activity without requiring further inference.

Helmy Eltoukhy, Co-CEO e direttore di Guardant Health (GH), ha presentato un Form 4 segnalando vendite nel mercato aperto delle azioni ordinarie dell’azienda in data 09/09/2025. La comunicazione mostra due transazioni di vendita: 294.723 azioni vendute a un prezzo medio ponderato di 59,4447 dollari e 5.277 azioni vendute a un prezzo medio ponderato di 59,9346 dollari. Dopo queste vendite la proprietà beneficiaria reportata era rispettivamente 2.128.776 azioni e 2.123.499 azioni. Le note a piè pagina indicano che il blocco più grande è stato venduto a prezzi che vanno da 58,79 a 59,78 dollari e il blocco minore da 59,79 a 60,25 dollari, con un prezzo medio ponderato riportato per ciascun blocco.

Il Form 4 è firmato da un procuratore ad acta per conto del signor Eltoukhy e non contiene ulteriori commenti, operazioni su opzioni o altre attività derivanti.

Helmy Eltoukhy, co-CEO y director de Guardant Health (GH), presentó un Formulario 4 informando ventas en el mercado abierto de las acciones comunes de la compañía el 09/09/2025. La presentación muestra dos transacciones de venta: 294.723 acciones vendidas a un precio medio ponderado de 59,4447 dólares y 5.277 acciones vendidas a un precio medio ponderado de 59,9346 dólares. Después de estas ventas, la titularidad beneficiosa reportada fue 2.128.776 acciones y 2.123.499 acciones, respectivamente. Las notas al pie señalan que el bloque más grande se vendió a precios entre 58,79 y 59,78 dólares y el bloque más pequeño entre 59,79 y 60,25 dólares, con un precio medio ponderado informado para cada bloque. El Formulario 4 está firmado por un apoderado en nombre del señor Eltoukhy y no contiene comentarios adicionales, transacciones de opciones u otra actividad derivada.

헬미 엘투키(Helmy Eltoukhy), Guardant Health(GH)의 공동 최고경영자(CEO) 겸 이사, 2025년 9월 9일 공시된 Form 4를 통해 회사의 보통주를 공개시장에서 매도했다는 정보를 제출했습니다. 공시에는 두 건의 매도 거래가 표시됩니다: 29만 4723주가 가중평균가 59.4447달러로 매도5,277주가 가중평균가 59.9346달러로 매도. 이 매도 후 보고된 수혜 소유권은 각각 2,128,776주2,123,499주로 기재됩니다. 각 블록에 대해 가중평균가가 보고되었으며, 주석에 따르면 대형 블록은 58.79~59.78달러 구간에서, 소형 블록은 59.79~60.25달러 구간에서 매도된 것으로 기재되어 있습니다.

Form 4는 엘투키 씨를 대신하여 대리인이 서명했고, 추가 코멘트나 옵션 거래, 또는 기타 파생상품 활동은 포함되어 있지 않습니다.

Helmy Eltoukhy, co-PDG et administrateur de Guardant Health (GH), a déposé un Formulaire 4 déclarant des ventes sur le marché libre d’actions ordinaires de la société le 09/09/2025. Le dépôt montre deux transactions de vente : telles que 294 723 actions vendues à un prix moyen pondéré de 59,4447 $ et 5 277 actions vendues à un prix moyen pondéré de 59,9346 $. Après ces ventes, la propriété bénéficiaire déclarée était respectivement 2 128 776 actions et 2 123 499 actions. Les notes de bas de page indiquent que le bloc le plus important a été vendu à des prix allant de 58,79 $ à 59,78 $ et le bloc le plus petit de 59,79 $ à 60,25 $, avec un prix moyen pondéré affiché pour chaque bloc. Le Formulaire 4 est signé par un mandataire agissant au nom de M. Eltoukhy et ne contient aucun commentaire supplémentaire, ni transactions d’options ou autres activités dérivées.

Helmy Eltoukhy, Co-CEO und Direktor von Guardant Health (GH), hat ein Form 4 eingereicht, das Offenmarktverkäufe von Stammaktien des Unternehmens am 09.09.2025 meldet. Die Einreichung zeigt zwei Verkaufstransaktionen: 294.723 Aktien zu einem gewichteten Durchschnittspreis von 59,4447 USD und 5.277 Aktien zu einem gewichteten Durchschnittspreis von 59,9346 USD. Nach diesen Verkäufen betrug die gemeldete wirtschaftliche Eigentümerschaft jeweils 2.128.776 Aktien bzw. 2.123.499 Aktien. Fußnoten geben an, dass der größere Block zu Preisen zwischen 58,79 USD und 59,78 USD verkauft wurde und der kleinere Block zwischen 59,79 USD und 60,25 USD, mit einem gewichteten Durchschnittspreis für jeden Block. Das Form 4 ist von einem Bevollmächtigten im Namen von Herrn Eltoukhy unterzeichnet und enthält keine weiteren Kommentare, Optionsgeschäfte oder andere Derivateaktivitäten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Eltoukhy Helmy

(Last) (First) (Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CA 94304

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Co-Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/09/2025 S 294,723(1) D $59.4447 2,128,776 D
Common Stock 09/09/2025 S 5,277(2) D $59.9346 2,123,499 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.79 to $59.78 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.79 to $60.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks:
/s/ John G. Saia, as attorney-in-fact for Helmy Eltoukhy 09/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Guardant Health (GH) insider Helmy Eltoukhy sell on 09/09/2025?

The Form 4 reports sales of 294,723 shares at a weighted average price of $59.4447 and 5,277 shares at a weighted average price of $59.9346 on 09/09/2025.

How many Guardant Health shares did Helmy Eltoukhy own after the reported sales?

The filing shows beneficial ownership of 2,128,776 shares following the larger sale and 2,123,499 shares following the smaller sale.

Were the sale prices for the shares reported as single prices or ranges?

Each sale reports a weighted average price and a footnote with the trade price ranges: the 294,723-share block traded between $58.79 and $59.78; the 5,277-share block traded between $59.79 and $60.25.

Was the sale executed under a Rule 10b5-1 trading plan according to the Form 4?

No. The Form 4 does not indicate that the transactions were made pursuant to a Rule 10b5-1 plan; the related checkbox is not marked.

Who signed the Form 4 for Helmy Eltoukhy?

The Form 4 is signed by John G. Saia, as attorney-in-fact for Helmy Eltoukhy, with signature dated 09/11/2025.
Guardant Health

NASDAQ:GH

GH Rankings

GH Latest News

GH Latest SEC Filings

GH Stock Data

7.05B
119.04M
4.5%
99.11%
6.43%
Diagnostics & Research
Services-medical Laboratories
Link
United States
PALO ALTO